ADDED CLAIMS

18. (new) A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H_2 agonist, in an amount sufficient that said histamine H_2 agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering said compound comprising administering monoamine oxidase-A to said patient so as to increase neuronal metabolism of tele-methylhistamine to an H_2 agonist.

19. (new) A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H_2 agonist, in an amount sufficient that said histamine H_2 agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering a compound comprising administering a histamine H_3 antagonist to said patient so as to inhibit neuronal metabolism of tele-methylhistamine to an H_3 antagonist and thereby increase neuronal metabolism of tele-methylhistamine to an H_2 agonist.

20. (new) The method of claim 19, wherein said histamine H_3 antagonist is thioperamide maleate.

21. (new) A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of:

administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H_2 agonist, in an amount sufficient that said histamine H_2 agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration;

the step of administering said compound comprising administering a monoamine oxidase-A agonist to said patient so as to increase neuronal metabolism of tele-methylhistamine to an H_2 agonist.

22. (new) The method of claim 21, wherein said monoamine oxidase-A agonist is reserpine.

23. (new) The method of claim 22, wherein the step of administering said monoamine oxidase-A agonist comprises:

administering reserpine by slow-release transdermal dose.

24. (new) The method of claim 21, wherein the step of administering said monoamine oxidase-A agonist comprises:

administering reserpine by injection in the range from about 1-10 mg/kg S.C. per day.